Unexpected medical issue grounds Isle Royale wolf-moose survey
Isle Royale is a 134,000-acre (54,200-hectare) island in far western Lake Superior between Grand Marais, Minnesota, and Thunder Bay, Canada. The island, which doubles as a national park, offers scientists a rare chance to observe wolves and moose in their natural habitat, free from human influence. Researchers have conducted an annual survey of the island's wolf and moose population since 1958.
Scientists from Michigan Tech University had planned to return to the island in January to conduct seven weeks of aerial surveys by ski-planes. Snow and bare branches make tracking easier from the air in winter, but the island lacks a land-based runway, forcing the scientists to use ski-planes that can land in the island's ice-covered harbors.
The scientists released their annual report on Tuesday, but it does not include any new population estimates. The report notes that the researchers were not able to get into the air at all this winter because 'our usual aviation resources became unexpectedly unavailable due to extenuating circumstances and there was insufficient time to find a suitable alternative.'
Michigan Tech spokesperson Hailey Hart explained in a telephone interview that the ski-plane pilot developed a last-minute medical issue and couldn't fly. The scientists were unable to find a replacement pilot.
'It was very sudden,' Hart said. 'It was a big bummer for them.'
Wednesdays
Columnist Jen Zoratti looks at what's next in arts, life and pop culture.
Researchers have experienced disruptions in three of the last five years they've attempted the survey. The COVID-19 pandemic forced them to cancel the survey in 2021, marking the first time since 1958 that population counts weren't conducted.
They had to cut the survey short in February 2024 after weeks of unusually warm weather left the ice surrounding the island unsafe for ski-plane landings. The National Park Service suspended the researchers' work and ordered them to evacuate.
Data the scientists gathered before they left showed the wolf population stood at 30 animals, down from 31 the previous year. The moose population stood at 840, down 14% from 2023.
Most of Tuesday's report discusses observations a group of college students made on the island in the summer of 2024. They noted regular wolf sightings, observed a wolf chasing a moose and found the bones of a wolf that died a decade ago, well before the park service began relocating wolves to the island in 2018. The students also found the remains of 115 moose, including 22 believed to have died in 2024. Researchers believe wolves killed all but three of those moose.
Hart said the scientists are planning another aerial survey next winter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
a day ago
Breaking down how a massive U.S. funding cut could impact future mRNA vaccines
The Trump administration says it is pulling half a billion dollars from U.S. government-funded research projects to create new mRNA vaccines. In a statement this week, U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, announced a co-ordinated wind-down amounting to the cancellation of $500 million worth (new window) of mRNA vaccine development under the Biomedical Advanced Research and Development Authority (BARDA). The technology itself was hailed as recently as the COVID-19 pandemic. In 2023, the Nobel Prize in (new window) Physiology or Medicine (new window) was awarded to two scientists whose mRNA discoveries made it possible to create COVID-19 vaccinations. The committee credited mRNA technology with helping to save millions of lives, prevent severe COVID-19, reduce disease burden and enable societies worldwide to reopen. The loss of research funding has dismayed infectious disease experts who note that mRNA technology allows faster production of shots than older vaccine-production methods, buying precious time if another pandemic virus were to emerge. Here's how medical experts in Canada and the U.S. are reacting to the funding cut and what they say it could mean. WATCH | The U.S. is ending mRNA vaccine funding: What is mRNA vaccine technology and why is it exciting? Vaccines train our immune system to respond to pathogens. Traditionally, vaccines have used inactive or weakened versions of a pathogen that isn't enough to make a person ill, but does kickstart the body's immune response. Messenger RNA (mRNA), discovered in 1961, is a natural molecule that serves as a recipe for the production of proteins in the body. In mRNA vaccines, the approach starts with a snippet of genetic code that carries instructions for making proteins. Scientists pick the protein to target, inject that blueprint into the body's cells, which then make just enough of the proteins to trigger an immune response — essentially producing its own vaccine dose. Scientists are mainly excited about the speed with which mRNA vaccines can get protection into arms. Enlarge image (new window) Dr. Drew Weissman and Katalin Karikó, PhD, struck up a working relationship when they met at the University of Pennsylvania in the 1990s. Together, he, an immunologist, and she, a biochemist, together won the 2023 Nobel Prize for Physiology or Medicine for the development of mRNA technology in Pfizer's and Moderna's COVID-19 vaccines. Photo: Peggy Peterson Photography/Penn Medicine/University of Pennsylvania Michael Osterholm, an expert on pandemic preparation with the University of Minnesota, says using older vaccine technology to target a pandemic flu strain would take 18 months to make enough doses to vaccinate only about one-fourth of the world. He says using mRNA technology to make a flu vaccine could change that timeline dramatically. By the end of the first year, we could vaccinate the world. Besides the advantage of how quickly mRNA vaccines can be made, Dr. Allison McGeer, an infectious diseases specialist in Toronto, says they're also easier to standardize. "It has a whole lot of other flexibilities that if you know it works, makes it a really exciting addition" to older technologies used to make vaccines. LISTEN | How mRNA vaccines went from medical miracle to political football (new window) What mRNA vaccine research is going on now? Beyond COVID vaccines, mRNA vaccine technology is in a Health Canada approved vaccine for respiratory syncytial virus (RSV). An mRNA vaccine for influenza has also reached Phase 3 clinical trial, the last step before manufacturers submit to regulators to release a vaccine to market. There have also been more than 100 clinical trials (new window) to assess the potential of mRNA vaccine technology to treat various cancers including lung, breast, prostate, melanoma and, more recently, pancreatic cancer (new window) . Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, says there's concern that cancelling funding for mRNA vaccine research will have negative consequences for research on other diseases. The mRNA technology is looking really exciting for next-generation cancer immunotherapeutics, said Hotez, who also works at Texas Children's Hospital Center for Vaccine Development. So will this throw cold water on a whole big effort that we're pursuing as well to develop next-generation cancer vaccine? That's an unknown question. Other research teams are testing potential mRNA-based vaccines to fight HIV (new window) and to treat autoimmune diseases (new window) . These are in early stage clinical trials or animal-stage studies. Enlarge image (new window) The technology used in mRNA vaccines, like the Pfizer-BioNTech COVID-19 vaccine seen being produced at the Allergopharma plant in Germany in April 2021, means they can be adapted to different diseases or variants. Infectious disease experts say this technology allows faster production of shots. Photo: AFP/Getty Images / Christian Charisius Could other countries pick up the slack? Though there are other countries working on mRNA vaccine technology, Hotez called the U.S. the single largest vaccine market. He says the announcement that funding was being cut could dissuade pharmaceutical companies from pursuing the vaccine technology if they believe it won't sell there. He says it's unclear whether other industrialized countries could pool their support to make up the $500 million US cut. Are there safety issues with mRNA vaccines as RFK Jr. suggested? In a video (new window) on the social media platform X, Kennedy claimed that mRNA vaccines were unsafe and ineffective. He said that after reviewing the science and consulting top U.S. experts, the department of Health and Human Services (HHS) has determined that mRNA technology poses more risk than benefits against these respiratory viruses. In the video, Kennedy also claimed that mRNA vaccines paradoxically encourage new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine. Angela Rasmussen, a virologist at the University of Saskatchewan, says Kennedy is wrong about what prolongs pandemics. WATCH | What RFK Jr. gets wrong on mRNA vaccines: Viruses mutate when they replicate, and they replicate when they spread through a population of people, Rasmussen said. The best way to prevent a virus from spreading through a population of people is to make sure those people are protected against the virus by vaccination. In a news release (new window) on Tuesday, Kennedy also referred to COVID and flu as upper respiratory infections, which Hotez notes is incorrect. Unlike the common cold, he says, COVID-19 and influenza are lower respiratory tract infections with significant cardiovascular and other health effects. That's part of the disinformation machine … to downplay the severity of these illnesses, said Hotez. Will lack of funding hurt access to existing flu vaccines? Rasmussen says influenza vaccines won't be affected in the U.S. as they're manufactured using the inactivated virus method, not mRNA. In the video posted to social media, Kennedy said the U.S. supports safe, effective vaccines for every American who wants them. But many infectious disease experts have noted that mRNA vaccines themselves are also safe and effective. The mRNA technology has been proven to be highly effective, Hotez said. By some estimates, 3.2 million American lives were saved by COVID mRNA vaccines during the pandemic. Amina Zafar (new window) · CBC News · Journalist Amina Zafar covers medical sciences and health care for CBC. She contributes to CBC Health's Second Opinion, which won silver for best editorial newsletter at the 2024 Digital Publishing Awards. She holds an undergraduate degree in environmental science and a master's in journalism. With files from CBC's Anand Ram and The Associated Press
Toronto Star
3 days ago
- Toronto Star
RFK Jr.‘s reasons for cutting mRNA vaccine not supported by evidence
Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service's recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology. The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes.
Toronto Star
3 days ago
- Toronto Star
FACT FOCUS: RFK Jr.‘s reasons for cutting mRNA vaccine not supported by evidence
Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service's recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology. The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes.
